Advanced search
Publication Cover
Biomarkers in Medicine Volume 3, 2009 - Issue 5
Submit an article Journal homepage
167
Views
1
CrossRef citations to date
0
Altmetric
Theme: Biomarkers: paving the way for better stratification in heart failure - Review

Cardiorenal Syndrome: Biomarkers Linking Kidney Damage with Heart Failure

Sachin S Soni1 Department of Nephrology,San Bortolo Hospital,Viale Rodolfi 37,36100 Vicenza,Italy. ;2 Renal Unit,Seth Nandlal Dhoot Hospital,Aurangabad,IndiaView further author information
,
Yuan Fahuan1 Department of Nephrology,San Bortolo Hospital,Viale Rodolfi 37,36100 Vicenza,Italy. View further author information
,
Claudio Ronco1 Department of Nephrology,San Bortolo Hospital,Viale Rodolfi 37,36100 Vicenza,Italy. ;3 International Renal Research Institute Vicenza (IRRIV),Vicenza,ItalyView further author information
&
Dinna N Cruz1 Department of Nephrology,San Bortolo Hospital,Viale Rodolfi 37,36100 Vicenza,Italy. ;3 International Renal Research Institute Vicenza (IRRIV),Vicenza,ItalyCorrespondence[email protected]
View further author information
Pages 549-560 | Published online: 08 Oct 2009

Bibliography

  • Ledoux P : [Cardiorenal syndrome.].Avenir Med.48(8), 149–153 (1951).
  • Odel HM , WeismanSJ: Salt-depletion syndrome as a complication in the treatment of cardiorenal disease.Med. Clin. North Am.1, 1145–1156 (1951).
  • Rakhlin AV : [Cardio-renal syndromes in various forms of endocarditis.].Klin. Med. (Mosk.)30(7), 63–72 (1952).
  • Meldrum DR , DonnahooKK: Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome.J. Surg. Res.85(2), 185–199 (1999).
  • Perunicic-Pekovic G , PljesaS, RasicZet al. : Relationship between inflammatory cytokines and cardiorenal anemia syndrome: treatment with recombinant human erythropoietin (rhepo).Hippokratia12(3), 153–156 (2008).
  • Pagourelias ED , KoumarasC, KakafikaAIet al. : Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?Angiology60(1), 74–81 (2009).
  • Tarng DC : Cardiorenal anemia syndrome in chronic kidney disease.J. Chin. Med. Assoc.70(10), 424–429 (2007).
  • Efstratiadis G , KonstantinouD, ChytasI, VergoulasG: Cardio-renal anemia syndrome.Hippokratia12(1), 11–16 (2008).
  • Palazzuoli A , GallottaM, IovineF, NutiR, SilverbergDS: Anaemia in heart failure: a common interaction with renal insufficiency called the cardio-renal anaemia syndrome.Int. J. Clin. Pract.62(2), 281–286 (2008).
  • Dimkovic S , DimkovicN: [The cardio-renal anemia syndrome].Med. Pregl.60(7–8), 357–363 (2007).
  • Cohen RS , MubashirA, WajahatR, ManiS, HummelS, MaurerMS: The cardio-renal-anemia syndrome in elderly subjects with heart failure and a normal ejection fraction: a comparison with heart failure and low ejection fraction.Congest. Heart Fail.12(4), 186–191 (2006).
  • Silverberg DS , WexlerD, IainaA, SteinbruchS, WollmanY, SchwartzD: Anemia, chronic renal disease and congestive heart failure – the cardiorenal anemia syndrome: the need for cooperation between cardiologists and nephrologists.Int. Urol. Nephrol.38(2), 295–310 (2006).
  • Silverberg DS , WexlerD, BlumMet al. : The interaction between heart failure, renal failure and anemia – the cardio-renal anemia syndrome.Blood Purif.22(3), 277–284 (2004).
  • Silverberg DS , WexlerD, IainaA: The role of anemia in congestive heart failure and chronic kidney insufficiency: the cardiorenal anemia syndrome.Perspect. Biol. Med.47(4), 575–589 (2004).
  • Siems W , QuastS, CarluccioFet al. : Oxidative stress in cardio renal anemia syndrome: correlations and therapeutic possibilities.Clin. Nephrol.60(Suppl. 1), S22–S30 (2003).
  • Celik T , IyisoyA, KursakliogluH, GungorM, YukselUC: Anemia and cardio-renal syndrome: a deadly association?Int. J. Cardiol.128(2), 255–256 (2008).
  • Liang KV , WilliamsAW, GreeneEL, RedfieldMM: Acute decompensated heart failure and the cardiorenal syndrome.Crit. Care Med.36(1 Suppl.), S75–S88 (2008).
  • Ronco C , HouseAA, HaapioM: Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong.Intensive Care Med.34(5), 957–962 (2008).
  • van der Putten K , BongartzLG, BraamB, GaillardCA: The cardiorenal syndrome a classification into 4 groups?J. Am. Coll. Cardiol.53(15), 1340; author reply 1340–1341 (2009).
  • Schrier RW : Cardiorenal versus renocardiac syndrome: is there a difference?Nat. Clin. Pract. Nephrol.3(12), 637 (2007).
  • Ronco C : Cardiorenal and renocardiac syndromes: clinical disorders in search of a systematic definition.Int. J. Artif. Organs31(1), 1–2 (2008).
  • Ronco C , HaapioM, HouseAA, AnavekarN, BellomoR: Cardiorenal syndrome.J. Am. Coll. Cardiol.52(19), 1527–1539 (2008).
  • Ronco C , ChionhCY, HaapioM, AnavekarNS, HouseA, BellomoR: The cardiorenal syndrome.Blood Purif.27(1), 114–126 (2009).
  • Dar O , CowieMR: Acute heart failure in the intensive care unit: epidemiology.Crit. Care Med.36(1 Suppl.), S3–S8 (2008).
  • Mebazaa A , GheorghiadeM, PinaILet al. : Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes.Crit. Care Med.36(1 Suppl.), S129–S139 (2008).
  • Adams KF , Jr., Fonarow GC, Emerman CL et al.: Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J.149(2), 209–216 (2005).
  • Fonarow GC , StoughWG, AbrahamWTet al. : Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.J. Am. Coll. Cardiol.50(8), 768–777 (2007).
  • Jose P , SkaliH, AnavekarNet al. : Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction.J. Am. Soc. Nephrol.17(10), 2886–2891 (2006).
  • Goldberg A , HammermanH, PetcherskiSet al. : Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction.Am. Heart J.150(2), 330–337 (2005).
  • Hillege HL , NitschD, PfefferMAet al. : Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.Circulation113(5), 671–678 (2006).
  • Bhatia RS , TuJV, LeeDSet al. : Outcome of heart failure with preserved ejection fraction in a population-based study.N. Engl. J. Med.355(3), 260–269 (2006).
  • Patel UD , OuFS, OhmanEMet al. : Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes.Am. J. Kidney Dis.53(3), 426–437 (2009).
  • Uchino S , BellomoR, GoldsmithD, BatesS, RoncoC: An assessment of the RIFLE criteria for acute renal failure in hospitalized patients.Crit. Care Med.34(7), 1913–1917 (2006).
  • Bagshaw SM , GeorgeC, DinuI, BellomoR: A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients.Nephrol. Dial. Transplant.23(4), 1203–1210 (2008).
  • Sarnak MJ , LeveyAS, SchoolwerthACet al. : Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.Hypertension42(5), 1050–1065 (2003).
  • Chertow GM , NormandSL, SilvaLR, McNeilBJ: Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project.Am. J. Kidney Dis.35(6), 1044–1051 (2000).
  • Aronow WS : Acute and chronic management of atrial fibrillation in patients with late-stage CKD.Am. J. Kidney Dis.53(4), 701–710 (2009).
  • Rucker D , TonelliM: Cardiovascular risk and management in chronic kidney disease.Nat. Rev. Nephrol.5(5), 287–296 (2009).
  • Herzog CA : Dismal long-term survival of dialysis patients after acute myocardial infarction: can we alter the outcome?Nephrol. Dial. Transplant.17(1), 7–10 (2002).
  • Johnson DW , CravenAM, IsbelNM: Modification of cardiovascular risk in hemodialysis patients: an evidence-based review.Hemodial. Int.11(1), 1–14 (2007).
  • Sarnak MJ , CoronadoBE, GreeneTet al. : Cardiovascular disease risk factors in chronic renal insufficiency.Clin. Nephrol.57(5), 327–335 (2002).
  • Go AS , ChertowGM, FanD, McCullochCE, HsuCY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N. Engl. J. Med.351(13), 1296–1305 (2004).
  • Coresh J , AstorBC, GreeneT, EknoyanG, LeveyAS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey.Am. J. Kidney Dis.41(1), 1–12 (2003).
  • Garg AX , ClarkWF, HaynesRB, HouseAA: Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I.Kidney Int.61(4), 1486–1494 (2002).
  • Keith DS , NicholsGA, GullionCM, BrownJB, SmithDH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization.Arch. Intern. Med.164(6), 659–663 (2004).
  • Logar CM , HerzogCA, BeddhuS: Diagnosis and therapy of coronary artery disease in renal failure, end-stage renal disease, and renal transplant populations.Am. J. Med. Sci.325(4), 214–227 (2003).
  • Collins AJ , LiS, GilbertsonDT, LiuJ, ChenSC, HerzogCA: Chronic kidney disease and cardiovascular disease in the Medicare population.Kidney Int. Suppl. (87), S24–S31 (2003).
  • Mukherjee D : Spatial distribution of coronary artery thromboses in patients with chronic kidney disease: implications for diagnosis and treatment.Kidney Int.75(1), 7–9 (2009).
  • Herzog CA : Kidney disease in cardiology.Nephrol. Dial. Transplant.24(1), 34–37 (2009).
  • Vincent JL , TacconeF, SchmitX: Classification, incidence, and outcomes of sepsis and multiple organ failure.Contrib. Nephrol.156, 64–74 (2007).
  • Ronco C : Preface.Contrib. Nephrol.156, XI–XII (2007).
  • Schrier RW , MasoumiA, ElhassanE: Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome.Blood Purif.27(1), 28–32 (2009).
  • Al-Hesayen A , ParkerJD: The effects of dobutamine on renal sympathetic activity in human heart failure.J. Cardiovasc. Pharmacol.51(5), 434–436 (2008).
  • Shestakova MV , Jarek-MartynowaIR, IvanishinaNSet al. : Role of endothelial dysfunction in the development of cardiorenal syndrome in patients with Type 1 diabetes mellitus.Diabetes Res. Clin. Pract.68(Suppl. 1), S65–S72 (2005).
  • Tsagalis G , ZerefosS, ZerefosN: Cardiorenal syndrome at different stages of chronic kidney disease.Int. J. Artif. Organs30(7), 564–576 (2007).
  • Heywood JT : The cardiorenal syndrome: lessons from the ADHERE database and treatment options.Heart Fail. Rev.9(3), 195–201 (2004).
  • Bulent Gul CB , GulluluM, OralBet al. : Urinary IL-18: a marker of contrast-induced nephropathy following percutaneous coronary intervention?Clin. Biochem.41(7–8), 544–547 (2008).
  • Sedghi Y , GaddamKK, VenturaHO: Emerging diuretics for the treatment of heart failure.Expert Opin. Emerg. Drugs14(1), 195–204 (2009).
  • Dohadwala MM , GivertzMM: Role of adenosine antagonism in the cardiorenal syndrome.Cardiovasc. Ther.26(4), 276–286 (2008).
  • Gottlieb SS : Adenosine A1 antagonists and the cardiorenal syndrome.Curr. Heart Fail. Rep.5(2), 105–109 (2008).
  • Pasquale PD , SarulloFM, PaternaS: Novel strategies: challenge loop diuretics and sodium management in heart failure – part I.Congest. Heart Fail.13(2), 93–98 (2007).
  • Bellomo R , AuriemmaS, FabbriAet al. : The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI).Int. J. Artif. Organs31(2), 166–178 (2008).
  • Bukowska A , LendeckelU, KrohnAet al. : Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney.Europace10(10), 1212–1217 (2008).
  • Khan T , HeywoodJT: Inpatient management of patients with volume overload and high filling pressures.J. Hosp. Med.3(6 Suppl.), S25–S32 (2008).
  • Holst M , StrombergA, LindholmM, WillenheimerR: Liberal versus restricted fluid prescription in stabilised patients with chronic heart failure: result of a randomised cross-over study of the effects on health-related quality of life, physical capacity, thirst and morbidity.Scand. Cardiovasc. J.42(5), 316–322 (2008).
  • Little WC : Heart failure with a normal left ventricular ejection fraction: diastolic heart failure.Trans. Am. Clin. Climatol. Assoc.119, 93–99; discussion 99–102 (2008).
  • Matsumoto Y , KageyamaS, YakushigawaTet al. : Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients.Cardiology114(1), 32–38 (2009).
  • Khanna A , WhiteWB: The management of hyperkalemia in patients with cardiovascular disease.Am. J. Med.122(3), 215–221 (2009).
  • Pitt B : Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fraction.Eur. Heart J.30(4), 387–388 (2009).
  • Tonelli M , SacksF, PfefferM, GaoZ, CurhanG: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease.Circulation112(17), 2627–2633 (2005).
  • Yeo FE , VillinesTC, BucciJR, TaylorAJ, AbbottKC: Cardiovascular risk in stage 4 and 5 nephropathy.Adv. Chronic Kidney Dis.11(2), 116–133 (2004).
  • Figueras J , SteinL, DiezV, WeilMH, ShubinH: Relationship between pulmonary hemodynamics and arterial pH and carbon dioxide tension in critically ill patients.Chest70(4), 466–472 (1976).
  • Brady JP , HasbargenJA: A review of the effects of correction of acidosis on nutrition in dialysis patients.Semin. Dial.13(4), 252–255 (2000).
  • McCullough PA , SandbergKR: Chronic kidney disease and sudden death: strategies for prevention.Blood Purif.22(1), 136–142 (2004).
  • Mardach R , VerityMA, CederbaumSD: Clinical, pathological, and biochemical studies in a patient with propionic acidemia and fatal cardiomyopathy.Mol. Genet. Metab.85(4), 286–290 (2005).
  • Joza N , OuditGY, BrownDet al. : Muscle-specific loss of apoptosis-inducing factor leads to mitochondrial dysfunction, skeletal muscle atrophy, and dilated cardiomyopathy.Mol. Cell. Biol.25(23), 10261–10272 (2005).
  • Blake P , HasegawaY, KhoslaMC, Fouad-TaraziF, SakuraN, PaganiniEP: Isolation of “myocardial depressant factor(s)” from the ultrafiltrate of heart failure patients with acute renal failure.ASAIO J.42(5), M911–M915 (1996).
  • Meyer TW , HostetterTH: Uremia.N. Engl. J. Med.357(13), 1316–1325 (2007).
  • Hooda AK , VarmaPP, DuttaV: Fatal cardiac tamponade in malarial acute renal failure.Ren. Fail.29(3), 371–373 (2007).
  • Banerjee A , DavenportA: Changing patterns of pericardial disease in patients with end-stage renal disease.Hemodial. Int.10(3), 249–255 (2006).
  • Sharma R , PellerinD, BreckerSJ: Cardiovascular disease in end stage renal disease.Minerva Urol. Nefrol.58(2), 117–131 (2006).
  • Grassi G , SeravalleG, Quarti-TrevanoF, Dell‘oroR: Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications.Curr. Vasc. Pharmacol.7(2), 137–145 (2009).
  • Grassi G , ArenareF, PieruzziF, BrambillaG, ManciaG: Sympathetic activation in cardiovascular and renal disease.J. Nephrol.22(2), 190–195 (2009).
  • Torres RA : Carotid body and sympathetic activation in heart failure: a story of sensors and sensitivity.Cardiovasc. Res.81(4), 633–634 (2009).
  • Bonderman D , MartischnigAM, MoertlD, LangIM: Pulmonary hypertension in chronic heart failure.Int. J. Clin. Pract. Suppl. (161), 4–10 (2009).
  • Crandall MA , HorneBD, DayJDet al. : Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently.Pacing Clin. Electrophysiol.32(5), 648–652 (2009).
  • Mahapatra HS , LalmalsawmaR, SinghNP, KumarM, TiwariSC: Cardiorenal syndrome.Iran. J. Kidney Dis.3(2), 61–70 (2009).
  • Ronco C : NGAL: an emerging biomarker of acute kidney injury.Int. J. Artif. Organs31(3), 199–200 (2008).
  • Devarajan P : Emerging biomarkers of acute kidney injury.Contrib. Nephrol.156, 203–212 (2007).
  • Vaidya VS , FergusonMA, BonventreJV: Biomarkers of acute kidney injury.Annu. Rev. Pharmacol. Toxicol.48, 463–493 (2008).
  • Maisel A , HollanderJE, GussDet al. : Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath.J. Am. Coll. Cardiol.44(6), 1328–1333 (2004).
  • Meyer B , HuelsmannM, WexbergPet al. : N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients.Crit. Care Med.35(10), 2268–2273 (2007).
  • Latini R , MassonS, AnandIet al. : The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.Eur. Heart J.25(4), 292–299 (2004).
  • Januzzi JL Jr, Camargo CA, Anwaruddin S et al.: The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am. J. Cardiol.95(8), 948–954 (2005).
  • McCullough PA , NowakRM, McCordJet al. : B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) multinational study.Circulation106(4), 416–422 (2002).
  • McCullough PA , SandbergKR: Sorting out the evidence on natriuretic peptides.Rev. Cardiovasc. Med.4(Suppl. 4), S13–S19 (2003).
  • Focaccio A , VolpeM, AmbrosioGet al. : Angiotensin II directly stimulates release of atrial natriuretic factor in isolated rabbit hearts.Circulation87(1), 192–198 (1993).
  • Munagala VK , BurnettJC Jr, Redfield MM: The natriuretic peptides in cardiovascular medicine. Curr. Probl. Cardiol.29(12), 707–769 (2004).
  • Schou M , DalsgaardMK, ClemmesenOet al. : Kidneys extract BNP and NT-proBNP in healthy young men.J. Appl. Physiol.99(5), 1676–1680 (2005).
  • Forfia PR , WatkinsSP, RameJE, StewartKJ, ShapiroEP: Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit.J. Am. Coll. Cardiol.45(10), 1667–1671 (2005).
  • McCullough PA , DucP, OmlandTet al. : B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly multinational study.Am. J. Kidney Dis.41(3), 571–579 (2003).
  • Vickery S , WebbMC, PriceCP, JohnRI, AbbasNA, LambEJ: Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population.Nephrol. Dial. Transplant.23(11), 3546–3553 (2008).
  • Satyan S , LightRP, AgarwalR: Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients.Am. J. Kidney Dis.50(6), 1009–1019 (2007).
  • Abbas NA , JohnRI, WebbMCet al. : Cardiac troponins and renal function in nondialysis patients with chronic kidney disease.Clin. Chem.51(11), 2059–2066 (2005).
  • Needham DM , ShufeltKA, TomlinsonG, ScholeyJW, NewtonGE: Troponin I and T levels in renal failure patients without acute coronary syndrome: a systematic review of the literature.Can. J. Cardiol.20(12), 1212–1218 (2004).
  • Frankel WL , HeroldDA, ZieglerTW, FitzgeraldRL: Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure.Am. J. Clin. Pathol.106(1), 118–123 (1996).
  • Resic H , AjanovicS, KukavicaN, MasnicF, CoricA: Plasma levels of brain natriuretic peptides and cardiac troponin in hemodialysis patients.Bosn. J. Basic Med. Sci.9(2), 137–141 (2009).
  • Hojs R : Cardiac troponin T in patients with kidney disease.Ther. Apher. Dial.9(3), 205–207 (2005).
  • Roberts MA , MacMillanN, HareDLet al. : Cardiac troponin levels in asymptomatic patients on the renal transplant waiting list.Nephrology (Carlton)11(5), 471–476 (2006).
  • Khan NA , HemmelgarnBR, TonelliM, ThompsonCR, LevinA: Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis.Circulation112(20), 3088–3096 (2005).
  • Kielstein JT , ZoccaliC: Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?Am. J. Kidney Dis.46(2), 186–202 (2005).
  • Zoccali C , MallamaciF, TripepiG: Traditional and emerging cardiovascular risk factors in end-stage renal disease.Kidney Int. Suppl. (85), S105–S110 (2003).
  • Tonelli M , WiebeN, CulletonBet al. : Chronic kidney disease and mortality risk: a systematic review.J. Am. Soc. Nephrol.17(7), 2034–2047 (2006).
  • Levin A , ThompsonCR, EthierJet al. : Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.Am. J. Kidney Dis.34(1), 125–134 (1999).
  • Bellomo R , KellumJA, RoncoC: Defining acute renal failure: physiological principles.Intensive Care Med.30(1), 33–37 (2004).
  • Devarajan P : Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease.Scand. J. Clin. Lab. Invest. Suppl.241, 89–94 (2008).
  • Liangos O , PerianayagamMC, VaidyaVSet al. : Urinary N-acetyl-β-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure.J. Am. Soc. Nephrol.18(3), 904–912 (2007).
  • Cowland JB , BorregaardN: Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans.Genomics45(1), 17–23 (1997).
  • Uttenthal O : A marker molecule for the distressed kidney?Clin. Lab. Int.29, 39–41 (2005).
  • Mori K , LeeHT, RapoportDet al. : Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury.J. Clin. Invest.115(3), 610–621 (2005).
  • Mishra J , MaQ, PradaAet al. : Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury.J. Am. Soc. Nephrol.14(10), 2534–2543 (2003).
  • Mishra J , MoriK, MaQ, KellyC, BaraschJ, DevarajanP: Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity.Am J. Nephrol.24(3), 307–315 (2004).
  • Schmidt-Ott KM , MoriK, KalandadzeAet al. : Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia.Curr. Opin. Nephrol. Hypertens.15(4), 442–449 (2006).
  • Mishra J , DentC, TarabishiRet al. : Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.Lancet365(9466), 1231–1238 (2005).
  • Hirsch R , DentC, PfriemHet al. : NGAL is an early predictive biomarker of contrast-induced nephropathy in children.Pediatr. Nephrol.22(12), 2089–2095 (2007).
  • Zappitelli M , WashburnKK, ArikanAAet al. : Urine neutrophil gelatinase- associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study.Crit. Care11(4), R84 (2007).
  • Wheeler DS , DevarajanP, MaQet al. : Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock.Crit. Care Med.36(4), 1297–1303 (2008).
  • Nickolas TL , O‘RourkeMJ, YangJet al. : Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury.Ann. Intern. Med.148(11), 810–819 (2008).
  • Bennett M , DentCL, MaQet al. : Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study.Clin. J. Am. Soc. Nephrol.3(3), 665–673 (2008).
  • Dent CL , MaQ, DastralaSet al. : Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study.Crit. Care11(6), R127 (2007).
  • Trachtman H , ChristenE, CnaanAet al. : Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury.Pediatr. Nephrol.21(7), 989–994 (2006).
  • Poniatowski B , MalyszkoJ, Bachorzewska-GajewskaH, MalyszkoJS, DobrzyckiS: Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease.Kidney Blood Press. Res.32(2), 77–80 (2009).
  • Damman K , van Veldhuisen DJ, Navis G, Voors AA, Hillege HL: Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur. J. Heart Fail.10(10), 997–1000 (2008).
  • Nguyen MT , DevarajanP: Biomarkers for the early detection of acute kidney injury.Pediatr. Nephrol.23(12), 2151–2157 (2008).
  • Herget-Rosenthal S , MarggrafG, HusingJet al. : Early detection of acute renal failure by serum cystatin C.Kidney Int.66(3), 1115–1122 (2004).
  • Koyner JL , BennettMR, WorcesterEMet al. : Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery.Kidney Int.74(8), 1059–1069 (2008).
  • Villa P , JimenezM, SorianoMC, ManzanaresJ, CasasnovasP: Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients.Crit. Care9(2), R139–R143 (2005).
  • Delanaye P , LambermontB, ChapelleJP, GielenJ, GerardP, RoriveG: Plasmatic cystatin C for the estimation of glomerular filtration rate in intensive care units.Intensive Care Med.30(5), 980–983 (2004).
  • Parikh CR , AbrahamE, AncukiewiczM, EdelsteinCL: Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit.J. Am. Soc. Nephrol.16(10), 3046–3052 (2005).
  • Parikh CR , MishraJ, Thiessen-PhilbrookHet al. : Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery.Kidney Int.70(1), 199–203 (2006).
  • Parikh CR , DevarajanP: New biomarkers of acute kidney injury.Crit. Care Med.36(4 Suppl.), S159–S165 (2008).
  • Haase M , BellomoR, StoryD, DavenportP, Haase-FielitzA: Urinary interleukin-18 does not predict acute kidney injury after adult cardiac surgery: a prospective observational cohort study.Crit. Care12(4), R96 (2008).
  • Ichimura T , BonventreJV, BaillyVet al. : Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury.J. Biol. Chem.273(7), 4135–4142 (1998).
  • Ichimura T , HungCC, YangSA, StevensJL, BonventreJV: Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury.Am. J. Physiol. Renal Physiol.286(3), F552–F563 (2004).
  • Han WK , BaillyV, AbichandaniR, ThadhaniR, BonventreJV: Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury.Kidney Int.62(1), 237–244 (2002).
  • Vaidya VS , RamirezV, IchimuraT, BobadillaNA, BonventreJV: Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury.Am. J. Physiol. Renal Physiol.290(2), F517–F529 (2006).
  • Price RG : The role of NAG (N-acetyl-β-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity.Clin. Nephrol.38(Suppl. 1), S14–S19 (1992).
  • Wiland P , SwierkotJ, SzechinskiJ: N-acetyl-β-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment.Br. J. Rheumatol.36(1), 59–63 (1997).
  • Hartmann HG , BraedelHE, JutzlerGA: Detection of renal tubular lesions after abdominal aortography and selective renal arteriography by quantitative measurements of brush-border enzymes in the urine.Nephron39(2), 95–101 (1985).
  • Westhuyzen J , EndreZH, ReeceG, ReithDM, SaltissiD, MorganTJ: Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit.Nephrol. Dial. Transplant.18(3), 543–551 (2003).
  • Han WK , WaikarSS, JohnsonAet al. : Urinary biomarkers in the early diagnosis of acute kidney injury.Kidney Int.73(7), 863–869 (2008).
  • Sabry A , WafaI, El-DinAB, El-HadidyAM, HassanM: Early markers of renal injury in predicting outcome in thermal burn patients.Saudi J. Kidney Dis. Transpl.20(4), 632–638 (2009).
  • Abid O , SunQ, SugimotoK, MercanD, VincentJL: Predictive value of microalbuminuria in medical ICU patients: results of a pilot study.Chest120(6), 1984–1988 (2001).
  • Gansevoort RT , de Jong PE: The case for using albuminuria in staging chronic kidney disease. J. Am. Soc. Nephrol.20(3), 465–468 (2009).
  • Noiri E , DoiK, NegishiKet al. : Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury.Am. J. Physiol. Renal Physiol.296(4), F669–F679 (2009).
  • du Cheyron D , DaubinC, PoggioliJet al. : Urinary measurement of Na+/H+ exchanger isoform 3 (NHE3) protein as new marker of tubule injury in critically ill patients with ARF.Am. J. Kidney Dis.42(3), 497–506 (2003).
  • Portilla D , DentC, SugayaTet al. : Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery.Kidney Int.73(4), 465–472 (2008).
  • Nguyen MT , DentCL, RossGFet al. : Urinary aprotinin as a predictor of acute kidney injury after cardiac surgery in children receiving aprotinin therapy.Pediatr. Nephrol.23(8), 1317–1326 (2008).
  • Ho J , LucyM, KrokhinOet al. : Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case–control study.Am. J. Kidney Dis.53(4), 584–595 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.